Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical use of ezetimibe.

Alice Y Y Cheng1, Lawrence A Leiter

  • 1St Michael's Hospital, Toronto, Ontario.

The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique
|October 23, 2003
PubMed
Summary

Ezetimibe effectively lowers low-density lipoprotein cholesterol (LDL-C) when statins are insufficient or not tolerated. This cholesterol absorption inhibitor offers a safe alternative for cardiovascular disease prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining the Roles of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Management of Chronic Kidney Disease in Adults with Type 2 Diabetes With or Without Overweight/Obesity: An International Delphi Consensus.

Advances in therapy·2026
Same author

Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial.

Diabetes, obesity & metabolism·2026
Same author

Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes.

Diabetes, obesity & metabolism·2026
Same author

Evidence-Based Positioning of Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Management of Chronic Kidney Disease with Type 2 Diabetes and Overweight or Obesity: A Systematic Literature Review.

Advances in therapy·2026
Same author

Efficacy and hypoglycaemia outcomes of once-weekly insulin icodec versus once-daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1-5.

Diabetes, obesity & metabolism·2025
Same author

Insights into the Mechanism of Action of Tirzepatide: A Narrative Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2025

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Cardiovascular disease is the leading cause of death in Canada, despite pharmacological advances.
  • Low-density lipoprotein cholesterol (LDL-C) reduction is proven to decrease cardiovascular morbidity and mortality.
  • Many patients do not achieve recommended LDL-C levels due to statin side effects or dose limitations.

Purpose of the Study:

  • To evaluate ezetimibe, a cholesterol absorption inhibitor, as a therapeutic option for LDL-C reduction.
  • To assess the efficacy and safety of ezetimibe, alone or in combination with statins.
  • To identify patient populations who may benefit most from ezetimibe therapy.

Main Methods:

  • Review of existing evidence on ezetimibe's efficacy in lowering LDL-C.
  • Assessment of ezetimibe's impact on other lipid parameters (HDL-C, triglycerides).
  • Evaluation of ezetimibe's safety profile and drug interactions.

Main Results:

  • Ezetimibe monotherapy or combination therapy with statins reduces LDL-C by an additional 15-20%.
  • Ezetimibe provides lipid improvements comparable to a three-fold increase in statin dose.
  • Ezetimibe is safe, with a profile similar to placebo and no significant drug interactions observed.

Conclusions:

  • Ezetimibe is a safe and effective addition to LDL-C lowering regimens.
  • It is particularly beneficial for patients unable to reach LDL-C goals with statins alone, or those who cannot tolerate statins.
  • Ezetimibe offers a valuable therapeutic option for managing hypercholesterolemia and reducing cardiovascular risk.

Related Experiment Videos